Blood Pressure Control by Drug Group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)

被引:75
|
作者
Cushman, William C. [2 ]
Ford, Charles E. [1 ]
Einhorn, Paula T. [3 ]
Wright, Jackson T., Jr. [4 ]
Preston, Richard A. [5 ]
Davis, Barry R. [1 ]
Basile, Jan N. [6 ]
Whelton, Paul K. [7 ]
Weiss, Robert J. [8 ]
Bastien, Arnaud [9 ]
Courtney, Donald L. [10 ]
Hamilton, Bruce P. [11 ]
Kirchner, Kent [12 ]
Louis, Gail T. [13 ]
Retta, Tamrat M. [14 ]
Vidt, Donald G. [15 ]
机构
[1] Univ Texas Houston, Hlth Sci Ctr, Sch Publ Hlth, Houston, TX 77030 USA
[2] Vet Affairs Med Ctr, Memphis, TN USA
[3] NHLBI, Bethesda, MD 20892 USA
[4] Univ Hosp Cleveland, Gen Clin Res Ctr, Cleveland, OH 44106 USA
[5] Vet Affairs Med Ctr, Miami, FL 33125 USA
[6] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA
[7] Loyola Univ, Hlth Syst & Med Ctr, Maywood, IL 60153 USA
[8] Androscoggin Cardiol Associates, Auburn, ME USA
[9] Bristol Myers Squibb Co, Princeton, NJ USA
[10] DD Eisenhower Vet Affairs Med Ctr, Leavenworth, KS USA
[11] Vet Affairs Med Ctr, Baltimore, MD USA
[12] Vet Affairs Med Ctr, Jackson, MS USA
[13] Tulane Univ, Hlth Sci Ctr, New Orleans, LA 70118 USA
[14] Howard Univ, Hypertens & Lipid Clin, Washington, DC 20059 USA
[15] Cleveland Clin Fdn, Cleveland, OH 44195 USA
来源
JOURNAL OF CLINICAL HYPERTENSION | 2008年 / 10卷 / 10期
基金
美国国家卫生研究院;
关键词
D O I
10.1111/j.1751-7176.2008.00015.x
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Blood pressure (BP) control rates and number of antihypertensive medications were compared (average follow-up, 4.9 years) by randomized groups: chlorthalidone, 12.5-25 mg/d (n=15,255), amlodipine 2.5-10 mg/d (n=9048), or lisinopril 10-40 mg/d (n=9054) in a randomized double-blind hypertension trial. Participants were hypertensives aged 55 or older with additional cardiovascular risk factor(s), recruited from 623 centers. Additional agents from other classes were added as needed to achieve BP control. BP was reduced from 145/83 mm Hg (27% control) to 134/76 mm Hg (chlorthalidone, 68% control), 135/75 mm Hg (amlodipine, 66% control), and 136176 mm Hg (lisinopril, 61% control) by 5 years; the mean number of drugs prescribed was 1.9, 2.0, and 2.1, respectively. Only 28% (chlorthalidone), 24% (amlodipine), and 24% (lisinopril) were controlled on monotherapy. BP control was achieved in the majority of each randomized group-a greater proportion with chlorthalidone. Over time, providers and patients should expect multidrug therapy to achieve BP < 140/90 mm Hg in a majority of patients. J Clin Hypertens (Greenwich). 2008;1.0:751-760. (c) 2008 Le Jacq
引用
收藏
页码:751 / 760
页数:10
相关论文
共 50 条
  • [1] Blood pressure control in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Cushman, WC
    Ford, CE
    Cutler, JA
    Margolis, KL
    Davis, BR
    Grimm, RH
    [J]. CIRCULATION, 2002, 106 (19) : 476 - 476
  • [2] Angioedema in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)
    Piller, L
    Ford, C
    Davis, B
    Nwachuku, C
    Black, H
    Oparil, S
    Gappy, S
    Retta, T
    Probstfield, J
    [J]. AMERICAN JOURNAL OF HYPERTENSION, 2005, 18 (05) : 92A - 92A
  • [3] Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) - Practical implications
    Oparil, S
    [J]. HYPERTENSION, 2003, 41 (05) : 1006 - 1009
  • [4] Antihypertensive and lipid-lowering treatment to prevent heart attack (ALLHAT) trial: Interim results
    Davis, B
    Furberg, CD
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2000, 36 (01) : 325 - 325
  • [5] Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Margolis, Karen L.
    Piller, Linda B.
    Ford, Charles E.
    Henriquez, Mario A.
    Cushman, William C.
    Einhorn, Paula T.
    Colon, Pedro J., Sr.
    Vidt, Donald G.
    Christian, Rudell
    Wong, Nathan D.
    Wright, Jackson T., Jr.
    Goff, David C., Jr.
    [J]. HYPERTENSION, 2007, 50 (05) : 854 - 861
  • [6] Participant recruitment in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
    Pressel, S
    Davis, BR
    Louis, GT
    Whelton, P
    Adrogue, H
    Egan, D
    Farber, M
    Payne, G
    Probstfield, J
    Ward, H
    [J]. CONTROLLED CLINICAL TRIALS, 2001, 22 (06): : 674 - 686
  • [7] Blood pressure control in Hispanic participants in the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT).
    Margolis, KL
    Piller, LB
    Lewis, CE
    Goff, DC
    Cushman, WC
    Wright, JT
    Colon, PJ
    Ford, CE
    [J]. CIRCULATION, 2001, 103 (09) : 1348 - 1348
  • [8] Heterogeneity in Early Responses in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
    Dhruva, Sanket S.
    Huang, Chenxi
    Spatz, Erica S.
    Coppi, Andreas C.
    Warner, Frederick
    Li, Shu-Xia
    Lin, Haiqun
    Xu, Xiao
    Furberg, Curt D.
    Davis, Barry R.
    Pressel, Sara L.
    Coifman, Ronald R.
    Krumholz, Harlan M.
    [J]. HYPERTENSION, 2017, 70 (01) : 94 - 102
  • [10] The antihypertensive and lipid-lowering treatment to prevent heart attack trial
    Flack, JM
    Nasser, SA
    [J]. CURRENT HYPERTENSION REPORTS, 2003, 5 (03) : 189 - 191